

# James L Abbruzzese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2023310/publications.pdf>

Version: 2024-02-01

47  
papers

3,252  
citations

218677

26  
h-index

223800

46  
g-index

49  
all docs

49  
docs citations

49  
times ranked

4773  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. <i>Gastroenterology</i> , 2019, 157, 1413-1428.e11.	1.3	57
2	Specificity Protein Transcription Factors and Cancer: Opportunities for Drug Development. <i>Cancer Prevention Research</i> , 2018, 11, 371-382.	1.5	84
3	Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. <i>Diabetes</i> , 2017, 66, 1103-1110.	0.6	311
4	FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity. <i>Endocrinology</i> , 2016, 157, 4754-4769.	2.8	29
5	<scp>ABO</scp> nonâ€ type as a risk factor for thrombosis in patients with pancreatic cancer. <i>Cancer Medicine</i> , 2015, 4, 1651-1658.	2.8	18
6	Cyclopamine-Loaded Core-Cross-Linked Polymeric Micelles Enhance Radiation Response in Pancreatic Cancer and Pancreatic Stellate Cells. <i>Molecular Pharmaceutics</i> , 2015, 12, 2093-2100.	4.6	20
7	Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 489-498.	2.3	59
8	New Option for the Initial Management of Metastatic Pancreatic Cancer?. <i>Journal of Clinical Oncology</i> , 2014, 32, 2405-2407.	1.6	12
9	Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	28
10	SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. <i>Human Pathology</i> , 2014, 45, 456-463.	2.0	41
11	Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. <i>Human Pathology</i> , 2014, 45, 1015-1023.	2.0	18
12	Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE. <i>Blood</i> , 2013, 122, 580-580.	1.4	27
13	Body Mass Index and Obesity- and Diabetes-Associated Genotypes and Risk for Pancreatic Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 779-792.	2.5	79
14	Activator Protein-1 Has an Essential Role in Pancreatic Cancer Cells and Is Regulated by a Novel Akt-Mediated Mechanism. <i>Molecular Cancer Research</i> , 2009, 7, 745-754.	3.4	23
15	Reply:. <i>Hepatology</i> , 2009, 50, 994-994.	7.3	0
16	Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. <i>Nature Protocols</i> , 2009, 4, 1670-1680.	12.0	336
17	The convergence of cancer prevention and therapy in early-phase clinical drug development. <i>Cancer Cell</i> , 2004, 6, 321-326.	16.8	50
18	The Challenge of Pancreatic Cancer. <i>International Journal of Gastrointestinal Cancer</i> , 2003, 33, 1-2.	0.4	6

#	ARTICLE	IF	CITATIONS
19	New applications of gemcitabine and future directions in the management of pancreatic cancer. <i>Cancer</i> , 2002, 95, 941-945.	4.1	75
20	Past and present treatment of pancreatic adenocarcinoma: Chemotherapy as a standard treatment modality. <i>Seminars in Oncology</i> , 2002, 29, 2-8.	2.2	451
21	Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin. <i>Current Oncology Reports</i> , 2001, 3, 131-140.	4.0	44
22	Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration. <i>Annals of Surgical Oncology</i> , 2001, 8, 123-132.	1.5	326
23	Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2001, 92, 2364-2373.	4.1	46
24	Mouse Models of Metastatic Pancreatic Adenocarcinoma. <i>International Journal of Gastrointestinal Cancer</i> , 2001, 29, 25-36.	0.4	14
25	A Novel, Clinically Relevant Animal Model of Metastatic Pancreatic Adenocarcinoma Biology and Therapy. <i>International Journal of Gastrointestinal Cancer</i> , 2001, 29, 37-46.	0.4	30
26	Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. <i>Oncogene</i> , 2001, 20, 3751-3756.	5.9	219
27	Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration. <i>Annals of Surgical Oncology</i> , 2001, 8, 123-132.	1.5	94
28	Tumor Suppressor Gene Smad4/DPC4, Its Downstream Target Genes, and Regulation of Cell Cycle. <i>Annals of the New York Academy of Sciences</i> , 1999, 880, 31-37.	3.8	27
29	Chemoradiation for Localized Pancreatic Cancer: Another Perspective. <i>Annals of Surgical Oncology</i> , 1999, 6, 4-7.	1.5	5
30	Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 1998, 5, 242-250.	2.0	37
31	Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. <i>Annals of Surgical Oncology</i> , 1998, 5, 681-688.	1.5	111
32	Cell cycle regulation of human pancreatic cancer by tamoxifen. <i>Annals of Surgical Oncology</i> , 1998, 5, 342-349.	1.5	17
33	Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique. <i>Annals of Surgical Oncology</i> , 1996, 3, 241-246.	1.5	21
34	Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells. <i>International Journal of Gastrointestinal Cancer</i> , 1996, 19, 31-38.	0.4	31
35	A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. <i>Cancer</i> , 1996, 78, 627-632.	4.1	73
36	A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. , 1996, 78, 627-632.		62

#	ARTICLE	IF	CITATIONS
37	A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. <i>Cancer</i> , 1996, 78, 627-632.	4.1	25
38	Randomized phase III Study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer. <i>Cancer</i> , 1995, 76, 1709-1714.	4.1	14
39	Preoperative chemoradiation for adenocarcinoma of the pancreas: M.D. Anderson experience. <i>Journal of Surgical Oncology</i> , 1995, 11, 132-140.	1.4	6
40	A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. <i>Cancer</i> , 1993, 72, 2560-2563.	4.1	5
41	Phase II study of didemnin B in advanced colorectal cancer. <i>Investigational New Drugs</i> , 1992, 10, 211-213.	2.6	17
42	Phase II study of gemcitabine in advanced colorectal adenocarcinoma. <i>Investigational New Drugs</i> , 1992, 10, 323-325.	2.6	35
43	Saturation of 2', 2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 27, 258-262.	2.3	235
44	Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 159-162.	2.3	5
45	Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 223-226.	2.3	13
46	Phase II study of Adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 24, 41-4.	2.3	4
47	Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. <i>Investigational New Drugs</i> , 1988, 6, 47-50.	2.6	11